Table 3.

Differences between the baseline and after 6 weeks of the MMD in each group for VAS and HIT-6 scores.

	Group A			Group B			Δ% Baseline–t1
Parameters	Baseline	t1	p-value	Baseline	t1	p-value	Group A	Group B	p-value
	Median ± [min. –max. value]			Median ± [min. –max. value]			Median ± [min. –max. value]
HIT-6 score	64.0 ± [54.0–70.0]	42.0 ± [38.0–48.0]	0.001**	62.5 ± [56.0–70.0]	61.5 ± [55.0–68.0]	0.100	−33.3 ± [−25.0 to −42.0]	−10.0 ± [0 to −13.0]	<0.001***
VAS	8.0 ± [5.0–9.0]	2.0 ± [1.0–5.0]	0.001**	7.0 ± [5.0–10.0]	6.0 ± [5.0–9.0]	0.080	−73.2 ± [−37.0–−83.0]	−26.7 ± [0 to −33.0]	<0.001***
PLR	61.0 ± [50.0–69.0]	40.0 ± [35.5–45.0]	0.040*	60.0 ± [50.0–68.5]	58.0 ± [55.0–63.5]	0.300	−41.0 ± [−33.3 to −53.3]	−10.0 ± [−10.0 to −13.0]	0.070
NLR	1.0 ± [0.8–1.2]	0.4 ± [0.3–0.45]	0.020*	1.0 ± [0.7–1.2]	0.80 ± [0.5–0.9]	0.200	−63.0 ± [−60.0 to −66.6]	−19.0 ± [−10.0 to −20.0]	0.020*
Ketoprofen (mg/week)	130.0 ± [40.0–280.0]	0 ± [0–20.0]	0.002**	120.0 ± [40.0–160.0]	100.0 ± [20.0–120.0]	0.200	−100.0 ± [−50 to −100]	−17.0 ± [0 to −30.0]	0.040*

Values are expressed as median, minimum, and maximum values (Median ± [min.–max. value]) for continuous variables. Differences between both groups of dietary intervention from baseline to t1 were performed Wilcoxon signed-rank test, while Δ% Baseline−4 weeks differences between the groups were compared by Mann-Whitney test. Statistical significance was attributed as *p < 0.05; **p < 0.01; ***p < 0.001). The Shapiro-Wilk test was performed to evaluate the variable distribution. Variables are considered non-normally distributed for p < 0.05. HIT-6, Headache Impact Test; VAS, Visual Analog Scale.